Emilio Alba

Neoadjuvant Abemaciclib plus Letrozole Versus Chemotherapy in Patients with HR+/HER2- Highly Proliferative Breast Can...

Clinical cancer research : an official journal of the American Association for Cancer Research · 2 maart 2026

Race and clinical outcomes in hormone receptor-positive, HER2-negative, node-positive breast cancer in the gerandomis...

Journal of the National Cancer Institute · 1 mei 2025

High Mechanical Conditioning by Tumor Extracellular Matrix Stiffness Is a Predictive Biomarker for Antifibrotic Thera...

Clinical cancer research : an official journal of the American Association for Cancer Research · 15 november 2024

OS met palbociclib plus endocriene therapie versus capecitabine bij mammacarcinoom: Young-PEARL update

European journal of cancer (Oxford, England : 1990) · 2022-06

21-genen assay en chemotherapievoordeel bij klierpositief mammacarcinoom: RxPONDER fase III

The New England journal of medicine · 16 december 2021

QoL met palbociclib plus endocriene therapie versus capecitabine bij mammacarcinoom

European journal of cancer (Oxford, England : 1990) · 2021-10

PAM50-gebaseerde chemo-endocriene score bij HR-positief mammacarcinoom met intermediair recidiefrisico

Clinical cancer research : an official journal of the American Association for Cancer Research · 15 juni 2017

18F-fluoromisonidazole PET en neoadjuvante nintedanib bij vroeg HER2-negatief mammacarcinoom: window-of-opportunity studie

Clinical cancer research : an official journal of the American Association for Cancer Research · 15 maart 2017

Ribociclib als eerstelijnstherapie bij HR-positief gevorderd mammacarcinoom: MONALEESA-2

The New England journal of medicine · 3 november 2016

Publicaties op Oncologisch.com